Savara Inc SVRA
News
Savara Announces Expanded Access Program (EAP) for Molgramostim Inhalation Solution (Molgramostim) for Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Savara Appoints Braden Parker as Chief Commercial Officer, Effective Immediately
Savara to Host Analyst and Investor Webinar on September 30, 2024
Savara Announces New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Were Presented at the European Respiratory Society (ERS) Congress 2024
Savara Announces New Employment Inducement Grant
Savara to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Savara Announces New Employment Inducement Grant
Savara to Present New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society (ERS) Congress 2024
Savara Reports Second Quarter 2024 Financial Results and Provides Business Update